Key Takeaways NVO's Ozempic and Wegovy generated DKK 50.1B in Q1 sales, making up 66% of total revenues. Label expansions and stronger access programs have fueled higher demand for semaglutide drugs. NVO secured a U.S. ban on mass compounding and is expanding Wegovy access via CVS and NovoCare.Novo Nordisk (NVO) generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II diabetes (T2D) and Wegovy for obesity. Ozempic and Wegovy include the same compound, semaglut ...

Key Takeaways LLY's tirzepatide drugs now drive 50% of revenues, with global demand fueling momentum. MRK relies heavily on Keytruda but faces headwinds in China and looming patent expirations. LLY forecasts up to 32% sales growth in 2025, while MRK's EPS and revenue estimates continue to decline.Both Eli Lilly (LLY) and Merck (MRK) are major players in the U.S. pharmaceutical industry, developing and commercializing therapies across oncology, immunology, and diabetes and cardiovascular areas. While Lilly ...

The CIA's proprietary airline for transporting illegal cargo (drugs, weapons, smuggled cash), Southern Air Transport, serviced St. Thomas in the US Virgin Islands, just 2 miles from Little Saint James (Epstein Island), which Epstein later bought. ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.Another potential competitor to blockbuster obesity treatments from Eli Lilly and Novo Nordisk just showed positive data – but this time, it's from China. An experimental weekly injection developed by Chinese drugmaker Hengrui Pharma and its U.S.-based partner, Kailera Therapeutics, succeeded in a late-stage trial in China, ...

Dublin man jailed over €9 million drugs haul https://t.co/CcLEDRgaku ...

A new study finding the use of weight loss drugs in kids has skyrocketed. Take a look at this. The study found that prescribing GLP1s for weight management in kids aged 8 to 17 increased 65% after the American Academy of Pediatrics issued guidelines recommending them 2 and a half years ago.Obviously, this was a recommendation by trusted pediatricians. But how young is too young for kids to go on these drugs. I mean, I think it's really a case-byase basis.The youngest in my practice is nine. But we look at o ...

Hims & Hers went from a scrappy startup to a telehealth powerhouse worth almost $11 billion in just a few years.@g0ingmad explains how the company became the king of knockoff weight-loss drugs https://t.co/MfO25SqQYd https://t.co/tFDtUrda7J ...

Key Takeaways Novo Nordisk stock is down 19.9% YTD due to weak obesity study data and regulatory headwinds. NVO faces stiff competition from Lilly's blockbuster GLP-1 drugs, including Zepbound and Mounjaro. Wegovy sales rose 83% in Q1 2025 and NVO is expanding semaglutide indications and manufacturing capacity.Novo Nordisk (NVO) shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and regulatory, that have led investors to bet against the company. The company r ...

10 July 2025 China Pharma and Biotech China Pharma & Biotech: recent rally, multiple expansions, and where we still see opportunities Rebecca Liang, Ph.D. +852 2123 2656 rebecca.liang@bernsteinsg.com Haopeng Zhou +852 2123 2630 haopeng.zhou@bernsteinsg.com William Pickering, MD +1 917 344 8340 william.pickering@bernsteinsg.com Louisa Qiu +1 917 344 8495 louisa.qiu@bernsteinsg.com Will the pharma / biotech rally go on? China healthcare is having the strongest rally since mid-2023. Hang Sang Biotech and MSCI ...

Irish police seize more than €2m of drugs https://t.co/WfBiRrSnYN ...